• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Lawsuit Delays the Cultivation of Medical Cannabis in Germany

November 14, 2017


German company Lexamed has successfully filed a lawsuit against the Federal Institute for Drugs and Medical Devices’ (BfArM) selection process for medical cannabis cultivation in Germany, delaying selection and implementation of the country’s medical cannabis cultivation program. Lexamed produces wheelchairs, rollators, and electric drives and wanted to invest in the cultivation of medical cannabis as early as possible, but at the end of June, BfArM rejected the company’s application.


At the beginning of June, 118 companies had applied for a medical cannabis cultivation-license in Germany. Until Lexamed’s appeal against the application criteria is heard by the Düsseldorf Higher Regional Court Dec. 20, official application evaluations, which should have been decided in October, are suspended.


Criteria Favors Experience


Generally, the BfArM regulates any production that must be done in compliance with the U.N.’s Single Convention on Narcotic Drugs of 1961, an international treaty that set regulations for the supply and production of specific drugs, including cannabis.


Cultivation applicants are required to meet many criteria to prove their capacity in the field of growing, processing, and supplying medical cannabis or growing phytomedicinal products in general. In a staged lottery, ten licenses are distributed by drawing lots among all applicants fulfilling the required criteria. For every hundred kg of cannabis grown, applicants earn 10 points, with a maximum of 40 points. So, if an applicant can prove they’ve already grown 200 kg of medical cannabis within the last three years, they will have already satisfied two-thirds of the minimum criteria. A maximum of 20 additional points is awarded based on references for the other herbal medicinal products.


If fewer than ten companies meet the requirements, licenses will be given to the applicants with the most points. Each cultivator is expected to deliver 200 kg of medical cannabis per year. For the period from 2019 to 2022, around 6.6 tonnes were scheduled for cultivation. To ensure each applicant is able to produce enough cannabis for a period of 65 months, up to seven lots per applicant may be awarded.


In order to achieve the maximum score of 60 points, candidates must demonstrate experience in growing at least 50 kilograms of medicinal cannabis within the last three years and have references in the cultivation field.


Only applicants who could prove they had already made finished drugs from medical herbs could earn the highest score.


Additionally, cannabis “made in Germany” will be subject to some of the strictest standards. In the Netherlands and Germany, test results for THC and CBD content must be within a +/- 10-percent deviation. In Canada and the Netherlands, the allowable deviation is 20 percent. For example, if a product is expected to test at 20 percent THC based on any previous testing, but tests at 35 percent, that’s allowable in Canada or the Netherlands as long as the THC percentage is clearly labeled on the product. In Germany, that crop would fail, so even if producers are awarded licenses to cultivate, they have very little room for error.


German Companies Alone Have No Chance


The catch is that applicants who did not partner with experienced companies from Canada, the Netherlands or Israel — countries with companies that meet the 200 kg cultivation criteria — would have been able to get in front of only 20 of the 60 possible points, putting them at a disadvantage. Partner companies from the United States did not meet the criteria, because cannabis production in several states is not subject to federal regulation, which, according to the Single Convention, renders the activities of U.S. producers generally illegal.


Numerous critics claim the selection criteria is tailored for large Phyto-Pharma companies and foreign investors. In principle, German startups have no chance of fulfilling the conditions given by the Federal Republic of Germany, because there has been no legal cultivation of cannabis in Germany. German cultivation activities could not be cited as a reference to earning the points necessary for their application to be approved.


“If the federal government had not tried to exclude German start-ups, various license-holders would already have taken first concrete steps to prepare production. Now there is the possibility that there will be significant delays,” Hanfverband CEO Georg Wurth told Marijuana.com.


What Now?


Until the objection is heard, the selection process is at a standstill. The judges considered the complaint as “not obviously hopeless” in September. If they agree with Lexamed’s lawyers, the current application procedure will be obsolete and the BfArM will need to develop other criteria, giving opportunities to companies that have not yet been able to grow cannabis due to the legal situation in their country.


Such a delay would throw the industry’s schedule back and delay the first crop for at least six months, aggravating an already unsatisfactory supply situation. If the litigious company’s complaint is dismissed, the first cultivation licenses, which should have been issued a month ago, could follow in January 2018. But even if the licenses are granted in January 2018, patients won’t be able to expect products on shelves before 2019.


This article was originally published on Marijuana.com


About Michael Knodt: Michael Knodt is an expert on cannabis politics and cannabis culture across Europe. Born in North Germany, Michael has been living in Berlin since 1990. He initially studied history and journalism before receiving his certification as a carpenter. Since then, Michael has made regular visits to countries where cannabis is cultivated, such as Jamaica and Morocco. He has worked as a freelancer for Weedmaps, Vice Magazine Germany, Sensi Seeds and numerous German-language cannabis magazines since 2004. From 2005 to 2013, Michael was the Editor-in-Chief of Germanys biggest cannabis periodical. He also is the face and presenter of the most popular program on cannabis prohibition and just launched a new channel called "DerMicha." Aside from his journalistic work, Michael is a cannabis patient, activist, sought-after speaker on conferences and congresses, and a father of two.

Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.